Tarsus Pharmaceuticals Inc. (TARS)
TARS trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1819790/000181979026000019/0001819790-26-000019-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | TARS on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2020 |
| SEC CIK | 0001819790 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $451.4M |
| Net income | -$66.4M |
| Operating income | -$71.0M |
| Net margin | -14.7% |
| Operating margin | -15.7% |
| Revenue growth | +146.7% |
| Cash | $183.6M |
| Total assets | $562.2M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 8.6× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-03 |
| Cash and burn | $136.5M cash; operating cash flow $12.5M a quarter. | Report 2026-09-30 |
| Shares outstanding | 49,305,552 (2026-10-29); 42,449,105 a year earlier; 33,104,612 three years earlier. | Cover page 2026-10-29 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 2 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-10-13 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, Irvine, California, United States | PCAOB Form AP 2026-03-09 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $20.0M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $194.6M | -$668.3M | -$6.0M | $136.5M | $72.9M | $682.2M | 10-Q 2026-11-03 |
| Q2 2026 2026-06-30 | $173.9M | -$18.6M | $61.2M | $204.6M | $72.8M | $606.3M | 10-Q 2026-08-06 |
| Q1 2026 2026-03-31 | $162.1M | -$7.0M | -$24.7M | $102.2M | $72.6M | $535.1M | 10-Q 2026-05-06 |
| Q4 2025 2025-12-31 | $151.7M | -$8.4M | $19.3M | $183.6M | $72.4M | $451.4M | 10-K 2026-02-23 |
| Q3 2025 2025-09-30 | $118.7M | -$12.6M | $18.3M | $112.7M | $72.3M | $366.1M | 10-Q 2026-11-03 |
| Q2 2025 2025-06-30 | $102.7M | -$20.3M | -$29.4M | $96.6M | $72.1M | $295.5M | 10-Q 2026-08-06 |
| Q1 2025 2025-03-31 | $78.3M | -$25.1M | -$20.7M | $175.8M | $72.0M | $233.7M | 10-Q 2026-05-06 |
| Q4 2024 2024-12-31 | $66.4M | -$23.1M | -$22.2M | $94.8M | $71.8M | $183.0M | 10-K 2026-02-23 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3ASR | 2026-10-13 |
| Latest annual report | 10-K | 2026-02-23 |
| Latest quarterly / interim | 10-Q | 2026-11-03 |
| Latest current report | 8-K | 2026-11-03 |
| Latest proxy | DEFA14A | 2026-04-28 |
Source: SEC EDGAR submissions feed, 678 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +17.0% |
| 1 month | +13.4% |
| 3 months | +16.6% |
| Year to date | -2.0% |
| 1 year | +10.7% |
| From 52-week high | -11.6% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| CRSP | CRISPR Therapeutics AG Common Shares | $40.37 | -4.43% | $3.9B |
| RLAY | Relay Therapeutics Inc. | $17.27 | -4.53% | $3.8B |
| IOVA | Iovance Biotherapeutics Inc. | $7.55 | -2.71% | $3.5B |
| ADPT | Adaptive Biotechnologies Corporation | $27.87 | -4.03% | $4.5B |
| ADMA | ADMA Biologics Inc | $13.47 | -1.54% | $3.0B |
| VCEL | Vericel Corporation | $57.48 | +0.91% | $2.9B |
| DNLI | Denali Therapeutics Inc. | $18.08 | -3.52% | $2.9B |
| SRRK | Scholar Rock Holding Corporation | $44.54 | +3.09% | $5.4B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier